voriconazole Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
systemic antifungal agents, miconazole derivatives 2846 137234-62-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • voriconazole
  • voriconazol
  • vfend
  • UK109496
  • UK-109496
  • UK 109496
A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.
  • Molecular weight: 349.32
  • Formula: C16H14F3N5O
  • CLOGP: 0.52
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 76.72
  • ALOGS: -3.55
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.39 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 34.35 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 96 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.42 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
May 24, 2002 FDA PF PRISM CV

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bronchopulmonary aspergillosis 659.94 16.44 212 21604 8453 53318797
Aspergillus infection 581.47 16.44 186 21630 7310 53319940
Drug interaction 399.86 16.44 469 21347 218860 53108390
Mucormycosis 333.06 16.44 95 21721 2505 53324745
Periostitis 298.82 16.44 58 21758 245 53327005
Multiple organ dysfunction syndrome 242.94 16.44 193 21623 55484 53271766
Drug level increased 205.79 16.44 119 21697 20302 53306948
Drug resistance 205.63 16.44 118 21698 19844 53307406
Photosensitivity reaction 201.80 16.44 103 21713 13725 53313525
Pneumonia fungal 180.73 16.44 69 21747 4587 53322663
Febrile neutropenia 179.95 16.44 218 21598 104718 53222532
Septic shock 176.89 16.44 169 21647 62060 53265190
Drug level below therapeutic 161.89 16.44 60 21756 3673 53323577
Fungal infection 143.16 16.44 113 21703 32133 53295117
Cerebral aspergillosis 141.03 16.44 33 21783 383 53326867
Cholestasis 134.85 16.44 104 21712 28591 53298659
Drug level decreased 133.56 16.44 62 21754 6712 53320538
Respiratory failure 130.37 16.44 182 21634 100330 53226920
Acute myeloid leukaemia 130.22 16.44 83 21733 16849 53310401
Graft versus host disease 124.51 16.44 60 21756 7062 53320188
Fatigue 124.04 16.44 73 21743 730433 52596817
Actinic keratosis 108.39 16.44 40 21776 2418 53324832
Dilatation intrahepatic duct acquired 107.35 16.44 30 21786 732 53326518
Scedosporium infection 103.71 16.44 27 21789 499 53326751
Pain 102.30 16.44 57 21759 588341 52738909
Pathogen resistance 99.00 16.44 50 21766 6510 53320740
Hallucination, visual 98.98 16.44 73 21743 18759 53308491
Systemic mycosis 92.50 16.44 29 21787 1063 53326187
Fusarium infection 90.09 16.44 25 21791 594 53326656
Drug ineffective 89.37 16.44 604 21212 816641 52510609
Hallucination 87.54 16.44 109 21707 53729 53273521
Pancytopenia 85.71 16.44 142 21674 90786 53236464
Visual impairment 81.32 16.44 123 21693 72789 53254461
Squamous cell carcinoma of skin 80.97 16.44 41 21775 5366 53321884
Photodermatosis 80.26 16.44 21 21795 396 53326854
Venoocclusive liver disease 78.35 16.44 38 21778 4534 53322716
Hepatotoxicity 75.90 16.44 74 21742 27806 53299444
Fluoride increased 71.91 16.44 12 21804 15 53327235
Sepsis 71.79 16.44 174 21642 146255 53180995
Fungaemia 69.46 16.44 28 21788 2149 53325101
Blood bilirubin increased 69.03 16.44 79 21737 35651 53291599
Geotrichum infection 68.40 16.44 19 21797 453 53326797
Keratitis fungal 63.05 16.44 14 21802 126 53327124
Pyrexia 61.71 16.44 326 21490 402867 52924383
Acute graft versus host disease in intestine 60.95 16.44 24 21792 1732 53325518
Torsade de pointes 60.77 16.44 47 21769 12958 53314292
Hypertrophic osteoarthropathy 60.64 16.44 11 21805 29 53327221
Joint swelling 59.17 16.44 12 21804 234626 53092624
Pneumonia 58.77 16.44 324 21492 406845 52920405
Graft versus host disease in gastrointestinal tract 57.94 16.44 27 21789 2947 53324303
Fall 54.89 16.44 40 21776 358400 52968850
Product use in unapproved indication 52.42 16.44 131 21685 112158 53215092
Blood alkaline phosphatase increased 52.21 16.44 74 21742 41288 53285962
Neurotoxicity 51.94 16.44 46 21770 15303 53311947
Acute graft versus host disease 51.17 16.44 28 21788 4289 53322961
Immunosuppressant drug level increased 51.15 16.44 26 21790 3429 53323821
Gamma-glutamyltransferase increased 49.88 16.44 65 21751 33490 53293760
Cytomegalovirus infection 49.72 16.44 50 21766 19489 53307761
Acute graft versus host disease in skin 49.44 16.44 25 21791 3261 53323989
Acute respiratory distress syndrome 49.19 16.44 54 21762 23278 53303972
Acute graft versus host disease in liver 49.08 16.44 16 21800 666 53326584
Thrombotic microangiopathy 48.62 16.44 36 21780 9301 53317949
Squamous cell carcinoma 48.39 16.44 34 21782 8098 53319152
Fungal test positive 48.12 16.44 15 21801 539 53326711
Hepatic function abnormal 48.03 16.44 67 21749 36832 53290418
Cytomegalovirus viraemia 47.38 16.44 28 21788 4963 53322287
Arthralgia 46.98 16.44 67 21749 439716 52887534
Acute myeloid leukaemia recurrent 46.69 16.44 19 21797 1494 53325756
Encephalopathy 46.67 16.44 66 21750 36742 53290508
Electrocardiogram QT prolonged 46.43 16.44 83 21733 56320 53270930
Arthropathy 46.04 16.44 3 21813 141450 53185800
Fluorosis 45.64 16.44 8 21808 16 53327234
Headache 44.47 16.44 96 21720 536725 52790525
Drug hypersensitivity 42.70 16.44 28 21788 265214 53062036
Graft versus host disease in skin 42.32 16.44 21 21795 2632 53324618
Pruritus 42.15 16.44 35 21781 293797 53033453
Swelling 41.93 16.44 13 21803 191092 53136158
Abdominal discomfort 40.34 16.44 20 21796 221042 53106208
Phaeohyphomycosis 39.89 16.44 11 21805 255 53326995
Strongyloidiasis 39.52 16.44 15 21801 980 53326270
Lentigo 39.18 16.44 11 21805 273 53326977
Maternal exposure during pregnancy 39.13 16.44 8 21808 155631 53171619
Musculoskeletal stiffness 39.03 16.44 3 21813 123365 53203885
Product dose omission issue 38.65 16.44 15 21801 191605 53135645
Chronic graft versus host disease 38.43 16.44 21 21795 3207 53324043
Nasopharyngitis 37.25 16.44 16 21800 192279 53134971
Therapeutic product effect decreased 37.22 16.44 4 21812 125651 53201599
Neutropenia 37.18 16.44 146 21670 159039 53168211
Mixed liver injury 37.17 16.44 22 21794 3911 53323339
Peripheral swelling 37.08 16.44 19 21797 206089 53121161
Corneal perforation 36.75 16.44 12 21804 502 53326748
Systemic candida 36.71 16.44 20 21796 3037 53324213
Liver function test abnormal 36.10 16.44 68 21748 48003 53279247
Aspergillus test positive 36.07 16.44 11 21805 367 53326883
Brain abscess 35.89 16.44 17 21799 1924 53325326
Hepatic cytolysis 35.76 16.44 28 21788 7857 53319393
Pneumonia bacterial 35.59 16.44 28 21788 7912 53319338
Halo vision 35.41 16.44 11 21805 391 53326859
Posterior reversible encephalopathy syndrome 35.10 16.44 38 21778 16122 53311128
Lung transplant rejection 35.03 16.44 13 21803 798 53326452
Dizziness 34.72 16.44 62 21754 372197 52955053
Trichosporon infection 34.64 16.44 10 21806 275 53326975
Exposure during pregnancy 34.49 16.44 5 21811 124855 53202395
Hypertransaminasaemia 34.17 16.44 21 21795 3995 53323255
Endophthalmitis 33.73 16.44 20 21796 3567 53323683
Solar lentigo 33.72 16.44 12 21804 653 53326597
Renal impairment 33.54 16.44 92 21724 83226 53244024
Rash 33.52 16.44 84 21732 446107 52881143
Hypersensitivity 32.87 16.44 23 21793 210642 53116608
Pain in extremity 32.86 16.44 41 21775 285009 53042241
Adenovirus infection 32.81 16.44 19 21797 3243 53324007
Pseudomonas infection 32.81 16.44 30 21786 10398 53316852
Platelet count decreased 32.77 16.44 108 21708 107991 53219259
Hepatocellular injury 32.57 16.44 50 21766 29936 53297314
Alopecia 32.34 16.44 29 21787 234554 53092696
Pulmonary alveolar haemorrhage 32.19 16.44 21 21795 4429 53322821
Immunosuppressant drug level decreased 32.17 16.44 13 21803 1004 53326246
Candida infection 31.56 16.44 45 21771 25228 53302022
Dyschromatopsia 31.30 16.44 10 21806 390 53326860
Toxic encephalopathy 31.19 16.44 23 21793 5904 53321346
Granulomatous liver disease 31.13 16.44 12 21804 818 53326432
Leukaemia recurrent 31.08 16.44 14 21802 1413 53325837
Aspergillus test 31.08 16.44 5 21811 4 53327246
Altered state of consciousness 30.69 16.44 44 21772 24792 53302458
Fungal endocarditis 30.40 16.44 9 21807 271 53326979
Urticaria 30.23 16.44 9 21807 135876 53191374
Infective aneurysm 30.16 16.44 10 21806 439 53326811
Bone marrow failure 29.64 16.44 48 21768 30067 53297183
Drug-induced liver injury 29.33 16.44 47 21769 29186 53298064
Aspartate aminotransferase increased 29.18 16.44 88 21728 83941 53243309
Lower respiratory tract infection fungal 29.10 16.44 9 21807 315 53326935
Chromatopsia 29.09 16.44 10 21806 491 53326759
Aspergilloma 28.83 16.44 8 21808 190 53327060
Acute kidney injury 28.83 16.44 190 21626 253678 53073572
Alanine aminotransferase increased 28.82 16.44 95 21721 95000 53232250
Graft versus host disease in liver 28.72 16.44 10 21806 510 53326740
Enterococcal infection 28.18 16.44 24 21792 7574 53319676
Photophobia 28.15 16.44 34 21782 16224 53311026
Delirium 27.93 16.44 56 21760 41373 53285877
Acute lymphocytic leukaemia recurrent 27.81 16.44 15 21801 2233 53325017
Myoclonus 27.35 16.44 33 21783 15731 53311519
Cerebral fungal infection 27.12 16.44 6 21810 53 53327197
Fungal skin infection 26.93 16.44 18 21798 3954 53323296
Cytokine release syndrome 26.78 16.44 24 21792 8105 53319145
Dermatitis bullous 26.69 16.44 24 21792 8139 53319111
Toxic epidermal necrolysis 26.61 16.44 40 21776 23510 53303740
Coccidioidomycosis 26.57 16.44 11 21805 904 53326346
Venoocclusive disease 26.23 16.44 14 21802 2041 53325209
Primary myelofibrosis 26.02 16.44 6 21810 65 53327185
Diarrhoea 26.00 16.44 150 21666 625396 52701854
Leukaemia 25.62 16.44 17 21799 3689 53323561
Colour blindness 25.39 16.44 8 21808 298 53326952
Haemoptysis 25.33 16.44 43 21773 27996 53299254
Urinary tract infection 25.11 16.44 37 21779 239866 53087384
Malaise 24.80 16.44 70 21746 357547 52969703
Staphylococcal infection 24.67 16.44 51 21765 38497 53288753
Pneumothorax 24.55 16.44 31 21785 15476 53311774
Wound 24.52 16.44 4 21812 91553 53235697
Disseminated intravascular coagulation 24.46 16.44 35 21781 19684 53307566
Death 24.45 16.44 238 21578 356994 52970256
Obliterative bronchiolitis 24.09 16.44 13 21803 1937 53325313
Anxiety 24.03 16.44 27 21789 196677 53130573
Weight increased 24 16.44 29 21787 204538 53122712
Infective pulmonary exacerbation of cystic fibrosis 23.82 16.44 26 21790 11130 53316120
Graft versus host disease in lung 23.81 16.44 8 21808 366 53326884
Nephropathy toxic 23.78 16.44 23 21793 8549 53318701
Nausea 23.68 16.44 197 21619 755894 52571356
Leukoencephalopathy 23.61 16.44 17 21799 4207 53323043
Respirovirus test positive 23.51 16.44 5 21811 36 53327214
Liver disorder 23.25 16.44 51 21765 40104 53287146
Bronchopulmonary aspergillosis allergic 23.09 16.44 11 21805 1261 53325989
Infusion related reaction 23.05 16.44 18 21798 155939 53171311
Sinusitis 23.02 16.44 21 21795 168543 53158707
Stenotrophomonas infection 22.64 16.44 12 21804 1724 53325526
Disease progression 22.58 16.44 92 21724 101828 53225422
Hyperlactacidaemia 22.55 16.44 14 21802 2711 53324539
Renal failure 22.46 16.44 102 21714 118350 53208900
Abdominal pain upper 22.38 16.44 21 21795 166270 53160980
Thrombocytopenia 22.37 16.44 114 21702 138613 53188637
Blood pressure increased 22.35 16.44 15 21801 140464 53186786
Bacterial sepsis 22.27 16.44 16 21800 3946 53323304
Chronic graft versus host disease in skin 22.17 16.44 9 21807 703 53326547
Infection reactivation 22.15 16.44 10 21806 1014 53326236
Pulmonary haemorrhage 21.92 16.44 20 21796 6913 53320337
Acute lymphocytic leukaemia 21.91 16.44 14 21802 2851 53324399
Skin candida 21.76 16.44 10 21806 1057 53326193
Pseudoaldosteronism 21.61 16.44 5 21811 55 53327195
Bacteraemia 21.38 16.44 29 21787 15520 53311730
Myocardial infarction 21.35 16.44 7 21809 99347 53227903
Pleural effusion 21.27 16.44 82 21734 88497 53238753
Tonsillitis bacterial 21.22 16.44 6 21810 153 53327097
Chronic papillomatous dermatitis 21.21 16.44 5 21811 60 53327190
Tracheobronchitis 20.97 16.44 10 21806 1149 53326101
Post transplant lymphoproliferative disorder 20.86 16.44 16 21800 4355 53322895
Scintillating scotoma 20.82 16.44 6 21810 164 53327086
Hepatic candidiasis 20.78 16.44 4 21812 16 53327234
Procalcitonin increased 20.65 16.44 9 21807 840 53326410
Palpitations 20.64 16.44 8 21808 102340 53224910
Aplastic anaemia 20.63 16.44 21 21795 8300 53318950
Asthenia 20.48 16.44 72 21744 343518 52983732
Drug ineffective for unapproved indication 20.35 16.44 33 21783 20687 53306563
Septal panniculitis 20.12 16.44 5 21811 76 53327174
Back pain 20.07 16.44 41 21775 234206 53093044
Off label use 20.03 16.44 287 21529 471925 52855325
Tuberculosis gastrointestinal 20.01 16.44 7 21809 362 53326888
Skin exfoliation 19.95 16.44 45 21771 36038 53291212
Encephalitis 19.61 16.44 20 21796 7924 53319326
Neutrophil count decreased 19.53 16.44 54 21762 49044 53278206
Cytomegalovirus enterocolitis 19.42 16.44 8 21808 649 53326601
Chest pain 19.25 16.44 30 21786 190155 53137095
Mucosal inflammation 18.98 16.44 49 21767 42735 53284515
Hypokalaemia 18.96 16.44 84 21732 96433 53230817
Disseminated cryptococcosis 18.70 16.44 7 21809 440 53326810
Dermatitis exfoliative 18.52 16.44 17 21799 5919 53321331
Migraine 18.49 16.44 5 21811 80412 53246838
Central nervous system fungal infection 18.38 16.44 5 21811 110 53327140
Necrosis 18.34 16.44 16 21800 5215 53322035
Agranulocytosis 18.33 16.44 34 21782 23715 53303535
Feeling abnormal 18.30 16.44 17 21799 135284 53191966
Cholecystitis acute 18.02 16.44 19 21797 7824 53319426
Disseminated trichosporonosis 18.01 16.44 4 21812 36 53327214
Hepatosplenic candidiasis 17.98 16.44 6 21810 269 53326981
Drug clearance decreased 17.92 16.44 9 21807 1157 53326093
Cystitis haemorrhagic 17.87 16.44 14 21802 3930 53323320
Osteomyelitis fungal 17.87 16.44 3 21813 4 53327246
Hallucination, auditory 17.79 16.44 23 21793 11750 53315500
Eye abscess 17.77 16.44 5 21811 125 53327125
Shock 17.70 16.44 33 21783 23106 53304144
Pulmonary mucormycosis 17.66 16.44 5 21811 128 53327122
Drug intolerance 17.57 16.44 36 21780 205457 53121793
Dyspepsia 17.51 16.44 5 21811 77595 53249655
Rash maculo-papular 17.46 16.44 38 21778 29711 53297539
Gastrooesophageal reflux disease 17.45 16.44 6 21810 82657 53244593
Laryngeal inflammation 17.34 16.44 5 21811 137 53327113
Arthritis 17.31 16.44 7 21809 87291 53239959
Bacterial infection 17.31 16.44 28 21788 17519 53309731
Cerebral haemorrhage 17.25 16.44 38 21778 29958 53297292
Flushing 16.98 16.44 4 21812 70596 53256654
Osteoarthritis 16.94 16.44 4 21812 70482 53256768
Disseminated aspergillosis 16.89 16.44 4 21812 49 53327201
Cytomegalovirus test positive 16.83 16.44 12 21804 2923 53324327
Impaired healing 16.76 16.44 3 21813 64202 53263048
Xanthopsia 16.63 16.44 5 21811 159 53327091
Stem cell transplant 16.60 16.44 10 21806 1835 53325415
Blood lactate dehydrogenase increased 16.58 16.44 31 21785 21750 53305500
Extraskeletal ossification 16.54 16.44 4 21812 54 53327196

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bronchopulmonary aspergillosis 845.77 14.06 371 34304 13316 32465535
Aspergillus infection 797.95 14.06 339 34336 11235 32467616
Photosensitivity reaction 645.62 14.06 281 34394 9882 32468969
Drug interaction 475.08 14.06 839 33836 217346 32261505
Drug level increased 418.88 14.06 263 34412 19817 32459034
Periostitis 326.19 14.06 72 34603 197 32478654
Mucormycosis 319.23 14.06 144 34531 5510 32473341
Actinic keratosis 311.26 14.06 127 34548 3783 32475068
Fungal infection 303.57 14.06 194 34481 15061 32463790
Cerebral aspergillosis 303.45 14.06 96 34579 1332 32477519
Drug ineffective 300.05 14.06 991 33684 382486 32096365
Drug resistance 228.26 14.06 192 34483 22773 32456078
Scedosporium infection 218.71 14.06 67 34608 830 32478021
Hallucination, visual 209.87 14.06 162 34513 16997 32461854
Squamous cell carcinoma of skin 203.02 14.06 128 34547 9698 32469153
Multiple organ dysfunction syndrome 200.18 14.06 305 34370 69549 32409302
Graft versus host disease 170.52 14.06 119 34556 10687 32468164
Hallucination 155.27 14.06 233 34442 52386 32426465
Photodermatosis 154.80 14.06 45 34630 459 32478392
Hepatotoxicity 148.97 14.06 140 34535 19197 32459654
Fatigue 148.58 14.06 96 34579 350605 32128246
Squamous cell carcinoma 139.46 14.06 106 34569 10862 32467989
Respiratory failure 138.06 14.06 333 34342 106849 32372002
Septic shock 137.26 14.06 256 34419 68733 32410118
Pneumonia fungal 130.19 14.06 82 34593 6198 32472653
Choroiditis 127.99 14.06 47 34628 1045 32477806
Condition aggravated 127.56 14.06 410 34265 155251 32323600
Endophthalmitis 122.65 14.06 67 34608 3882 32474969
Systemic mycosis 118.86 14.06 48 34627 1390 32477461
Pathogen resistance 116.71 14.06 90 34585 9420 32469431
Febrile neutropenia 108.09 14.06 326 34349 119240 32359611
Cholestasis 96.29 14.06 131 34544 26902 32451949
Visual impairment 96.04 14.06 145 34530 32743 32446108
Fluoride increased 93.68 14.06 20 34655 44 32478807
Solar lentigo 91.01 14.06 29 34646 412 32478439
Cheilitis 90.55 14.06 46 34629 2295 32476556
Drug level below therapeutic 90.03 14.06 56 34619 4139 32474712
Hepatic function abnormal 88.61 14.06 166 34509 44674 32434177
Completed suicide 85.32 14.06 3 34672 92514 32386337
Myocardial infarction 82.13 14.06 17 34658 125659 32353192
Dysplastic naevus 80.48 14.06 26 34649 387 32478464
Fall 79.77 14.06 56 34619 196145 32282706
Disseminated mucormycosis 79.17 14.06 23 34652 234 32478617
Fungaemia 78.63 14.06 43 34632 2496 32476355
Fusarium infection 75.15 14.06 32 34643 1062 32477789
Candida infection 74.87 14.06 91 34584 16712 32462139
Drug level decreased 74.75 14.06 59 34616 6387 32472464
Product dose omission issue 73.27 14.06 11 34664 102564 32376287
Acute myeloid leukaemia 71.45 14.06 95 34580 19079 32459772
Drug level above therapeutic 70.95 14.06 44 34631 3234 32475617
Drug abuse 69.42 14.06 4 34671 80239 32398612
Phaeohyphomycosis 68.62 14.06 28 34647 833 32478018
Immunosuppressant drug level increased 68.22 14.06 51 34624 5094 32473757
Pain 65.68 14.06 62 34613 187494 32291357
Mycotic endophthalmitis 61.27 14.06 14 34661 47 32478804
Aspergilloma 60.17 14.06 20 34655 327 32478524
Asthenia 59.68 14.06 100 34575 235844 32243007
Treatment failure 59.49 14.06 130 34545 39033 32439818
Dyspnoea 59.13 14.06 194 34481 361851 32117000
Dyschromatopsia 58.70 14.06 20 34655 354 32478497
Graft versus host disease in gastrointestinal tract 56.86 14.06 39 34636 3402 32475449
Fluorosis 55.52 14.06 13 34662 50 32478801
Visual acuity reduced 54.51 14.06 77 34598 16368 32462483
Depression 54.13 14.06 18 34657 97042 32381809
Trichosporon infection 53.77 14.06 23 34652 772 32478079
Nephropathy toxic 53.71 14.06 65 34610 11881 32466970
Intraocular pressure increased 53.49 14.06 46 34629 5612 32473239
Uveitis 52.80 14.06 48 34627 6302 32472549
Pseudomonas infection 51.61 14.06 64 34611 11992 32466859
Diarrhoea 51.29 14.06 208 34467 364594 32114257
Neurological symptom 50.36 14.06 37 34638 3598 32475253
Inappropriate antidiuretic hormone secretion 49.99 14.06 63 34612 12000 32466851
Acute myeloid leukaemia recurrent 49.79 14.06 29 34646 1901 32476950
Nausea 49.57 14.06 176 34499 320673 32158178
Brain abscess 47.88 14.06 33 34642 2901 32475950
Product use in unapproved indication 47.08 14.06 201 34474 87003 32391848
Pruritus 46.85 14.06 41 34634 128661 32350190
Anxiety 46.65 14.06 22 34653 95983 32382868
Dizziness 46.64 14.06 96 34579 209522 32269329
Hepatocellular injury 46.62 14.06 91 34584 25227 32453624
Constipation 46.32 14.06 40 34635 126333 32352518
Mediastinitis 46.02 14.06 20 34655 698 32478153
Disseminated intravascular coagulation 46.00 14.06 86 34589 23090 32455761
Geotrichum infection 45.03 14.06 18 34657 507 32478344
Liver disorder 44.61 14.06 102 34573 31552 32447299
Central nervous system fungal infection 44.46 14.06 16 34659 335 32478516
Chest pain 43.45 14.06 41 34634 124096 32354755
Neurotoxicity 43.34 14.06 66 34609 15004 32463847
Leukaemia recurrent 43.27 14.06 25 34650 1614 32477237
Drug ineffective for unapproved indication 42.97 14.06 63 34612 13849 32465002
Pain in extremity 41.93 14.06 39 34636 118862 32359989
Product compounding quality issue 41.79 14.06 9 34666 21 32478830
Blood pressure increased 40.41 14.06 17 34658 79337 32399514
Renal ischaemia 39.73 14.06 17 34658 571 32478280
Acute graft versus host disease 39.51 14.06 41 34634 6329 32472522
Eye pain 39.08 14.06 58 34617 12890 32465961
Photophobia 39.01 14.06 41 34634 6423 32472428
Cardiac failure congestive 38.89 14.06 21 34654 84831 32394020
Arthralgia 38.33 14.06 62 34613 148386 32330465
Xanthopsia 38.22 14.06 12 34663 162 32478689
Dehydration 38.08 14.06 49 34626 128909 32349942
Alternaria infection 37.56 14.06 14 34661 325 32478526
Peripheral swelling 37.53 14.06 13 34662 68332 32410519
Aspergillus test positive 36.92 14.06 15 34660 441 32478410
Pseudoporphyria 36.68 14.06 13 34662 260 32478591
Enterococcal infection 36.68 14.06 47 34628 9100 32469751
Acute graft versus host disease in liver 36.41 14.06 21 34654 1351 32477500
Rheumatoid arthritis 36.25 14.06 3 34672 44541 32434310
Burns second degree 36.07 14.06 14 34661 364 32478487
Cytomegalovirus viraemia 35.93 14.06 40 34635 6687 32472164
Cytokine release syndrome 35.75 14.06 57 34618 13478 32465373
Pneumonia 35.06 14.06 552 34123 354700 32124151
Enterococcal sepsis 35.06 14.06 22 34653 1651 32477200
Acute graft versus host disease in skin 34.58 14.06 34 34641 4923 32473928
Hepatitis cholestatic 34.14 14.06 43 34632 8182 32470669
Septic embolus 33.83 14.06 19 34656 1162 32477689
Weight decreased 33.73 14.06 79 34596 164739 32314112
Nasopharyngitis 33.56 14.06 13 34662 63774 32415077
Product contamination microbial 33.51 14.06 16 34659 697 32478154
Blood alkaline phosphatase increased 33.17 14.06 92 34583 32040 32446811
Scopulariopsis infection 32.77 14.06 10 34665 122 32478729
Nocardiosis 32.59 14.06 29 34646 3702 32475149
Vomiting 32.57 14.06 135 34540 235422 32243429
Eye infection fungal 32.56 14.06 13 34662 365 32478486
Lip squamous cell carcinoma 32.47 14.06 9 34666 76 32478775
Malaise 32.32 14.06 90 34585 177048 32301803
Hyperhidrosis 32.05 14.06 18 34657 71150 32407701
Back pain 31.95 14.06 43 34632 111010 32367841
Graft versus host disease in skin 31.45 14.06 28 34647 3576 32475275
Headache 31.31 14.06 106 34569 196091 32282760
Hypertension 31.29 14.06 58 34617 131692 32347159
Intentional overdose 30.77 14.06 4 34671 41597 32437254
Arthritis fungal 30.34 14.06 9 34666 99 32478752
Cystitis haemorrhagic 30.09 14.06 32 34643 5082 32473769
Post transplant lymphoproliferative disorder 29.98 14.06 34 34641 5800 32473051
Acute respiratory distress syndrome 29.81 14.06 76 34599 25177 32453674
Venoocclusive liver disease 29.77 14.06 38 34637 7327 32471524
Urinary tract infection 29.74 14.06 25 34650 80046 32398805
Disseminated aspergillosis 29.72 14.06 11 34664 250 32478601
Cerebrovascular accident 29.62 14.06 29 34646 86291 32392560
Toxic optic neuropathy 29.49 14.06 15 34660 750 32478101
Lentigo 29.37 14.06 12 34663 358 32478493
Macular opacity 29.22 14.06 5 34670 0 32478851
Asthma 28.67 14.06 6 34669 44059 32434792
Psoriasis 28.57 14.06 7 34668 46116 32432735
Pulmonary cavitation 28.46 14.06 15 34660 808 32478043
Inappropriate schedule of product administration 28.29 14.06 7 34668 45818 32433033
Torsade de pointes 28.01 14.06 37 34638 7378 32471473
Gallbladder oedema 27.85 14.06 10 34665 208 32478643
Hepatic failure 27.32 14.06 92 34583 35588 32443263
Drug-induced liver injury 26.95 14.06 71 34604 23992 32454859
Central nervous system lesion 26.65 14.06 32 34643 5800 32473051
Chronic graft versus host disease 26.50 14.06 28 34647 4412 32474439
Cytomegalovirus infection 26.37 14.06 73 34602 25391 32453460
Fungal endocarditis 26.36 14.06 10 34665 244 32478607
Pyrexia 26.34 14.06 483 34192 319485 32159366
Stenotrophomonas infection 26.29 14.06 19 34656 1801 32477050
Acanthamoeba keratitis 26.04 14.06 8 34667 100 32478751
Dyspnoea exertional 25.98 14.06 5 34670 38956 32439895
Lower respiratory tract infection fungal 25.94 14.06 13 34662 630 32478221
Gallbladder empyema 25.59 14.06 7 34668 56 32478795
Photopsia 25.39 14.06 19 34656 1900 32476951
Transmission of an infectious agent via product 25.16 14.06 9 34666 185 32478666
Muscle spasms 24.92 14.06 23 34652 70395 32408456
Injection site pain 24.88 14.06 3 34672 33055 32445796
Dyspepsia 24.88 14.06 3 34672 33052 32445799
Tongue necrosis 24.87 14.06 6 34669 27 32478824
Rectal haemorrhage 24.54 14.06 5 34670 37418 32441433
Fungal skin infection 24.32 14.06 21 34654 2576 32476275
Urticaria 24.19 14.06 17 34658 59597 32419254
Gastrooesophageal reflux disease 24.16 14.06 4 34671 34734 32444117
Nervous system disorder 24.06 14.06 49 34626 14000 32464851
Haemophagocytic lymphohistiocytosis 23.67 14.06 43 34632 11292 32467559
Chromatopsia 23.59 14.06 9 34666 223 32478628
Infectious pleural effusion 23.39 14.06 19 34656 2142 32476709
Gamma-glutamyltransferase increased 23.23 14.06 79 34596 30703 32448148
Osteomyelitis fungal 23.15 14.06 9 34666 235 32478616
Urinary bladder rupture 23.05 14.06 7 34668 84 32478767
Lung infiltration 22.93 14.06 46 34629 13002 32465849
Disease recurrence 22.89 14.06 52 34623 16012 32462839
Cerebral fungal infection 22.87 14.06 9 34666 243 32478608
Pulmonary haemorrhage 22.65 14.06 39 34636 9818 32469033
Acute graft versus host disease in intestine 22.47 14.06 20 34655 2553 32476298
Pulmonary embolism 22.46 14.06 34 34641 83625 32395226
Retinal ischaemia 22.44 14.06 10 34665 371 32478480
Abscess fungal 22.39 14.06 8 34667 164 32478687
Transaminases increased 22.31 14.06 68 34607 24960 32453891
Pancytopenia 22.24 14.06 170 34505 91065 32387786
Cytomegalovirus enterocolitis 22.15 14.06 13 34662 864 32477987
Hypertrophic osteoarthropathy 22.13 14.06 7 34668 97 32478754
Acute myocardial infarction 22.01 14.06 16 34659 55133 32423718
Off label use 22.00 14.06 453 34222 305867 32172984
Neutropenia 21.95 14.06 240 34435 141935 32336916
Halo vision 21.73 14.06 8 34667 179 32478672
Pulmonary alveolar haemorrhage 21.60 14.06 32 34643 7097 32471754
Ureaplasma infection 21.33 14.06 8 34667 189 32478662
BK virus infection 21.03 14.06 26 34649 4855 32473996
Angina pectoris 21.03 14.06 4 34671 31422 32447429
Sepsis 20.91 14.06 260 34415 158574 32320277
Altered state of consciousness 20.77 14.06 61 34614 21936 32456915
Musculoskeletal stiffness 20.65 14.06 8 34667 39256 32439595
Sunburn 20.25 14.06 16 34659 1734 32477117
Neuroendocrine carcinoma of the skin 20.17 14.06 11 34664 635 32478216
Klebsiella infection 20.14 14.06 33 34642 7979 32470872
Scintillating scotoma 20.13 14.06 5 34670 26 32478825
Meningitis coccidioides 19.97 14.06 5 34670 27 32478824
Peptic ulcer haemorrhage 19.94 14.06 10 34665 485 32478366
Pulmonary mass 19.88 14.06 41 34634 11819 32467032
Necrotising retinitis 19.78 14.06 12 34663 848 32478003
Systemic candida 19.74 14.06 20 34655 3001 32475850
Aplasia 19.69 14.06 24 34651 4418 32474433
Hallucinations, mixed 19.57 14.06 19 34656 2708 32476143
Drug hypersensitivity 19.54 14.06 30 34645 73370 32405481
Gait disturbance 19.43 14.06 35 34640 80373 32398478
Organising pneumonia 19.41 14.06 27 34648 5654 32473197
Prostate cancer 19.41 14.06 3 34672 27403 32451448
Syncope 19.39 14.06 42 34633 90082 32388769
Chloropsia 19.34 14.06 4 34671 7 32478844
Citrobacter infection 19.14 14.06 10 34665 529 32478322
Colour blindness acquired 19.11 14.06 6 34669 81 32478770
Splenic candidiasis 19.11 14.06 6 34669 81 32478770
Burns first degree 18.99 14.06 4 34671 8 32478843
Decreased appetite 18.74 14.06 98 34577 160715 32318136
Pulmonary mucormycosis 18.71 14.06 10 34665 554 32478297
Cerebral artery embolism 18.64 14.06 12 34663 941 32477910
Abdominal pain 18.64 14.06 89 34586 149440 32329411
Bacterial infection 18.48 14.06 44 34631 13962 32464889
Eye abscess 18.48 14.06 7 34668 170 32478681
Joint swelling 18.18 14.06 17 34658 51718 32427133
Toxic skin eruption 18.13 14.06 39 34636 11575 32467276
Retinal toxicity 18.04 14.06 9 34666 432 32478419
Intentional product misuse 17.90 14.06 8 34667 36043 32442808
Neurological decompensation 17.88 14.06 18 34657 2680 32476171
Oral papilloma 17.85 14.06 4 34671 12 32478839
Bacterial sepsis 17.80 14.06 25 34650 5283 32473568
Acute lymphocytic leukaemia recurrent 17.68 14.06 19 34656 3053 32475798
Mycobacterium abscessus infection 17.68 14.06 10 34665 620 32478231
Bronchial artery embolisation 17.53 14.06 3 34672 0 32478851
Staphylococcal sepsis 17.48 14.06 35 34640 9878 32468973
Abdominal pain upper 17.47 14.06 28 34647 67310 32411541
Retinal haemorrhage 17.36 14.06 24 34651 4997 32473854
Hospitalisation 17.32 14.06 16 34659 48955 32429896
Transplant rejection 17.27 14.06 35 34640 9964 32468887
Nephrolithiasis 17.23 14.06 4 34671 27350 32451501
Chronic obstructive pulmonary disease 17.16 14.06 16 34659 48737 32430114
Wrong technique in product usage process 17.07 14.06 8 34667 35051 32443800
Inhibitory drug interaction 17.01 14.06 14 34661 1607 32477244
Gastrointestinal wall thinning 16.96 14.06 4 34671 16 32478835
Hyperammonaemia 16.96 14.06 26 34649 5943 32472908
Flushing 16.94 14.06 6 34669 31121 32447730
Leukaemia 16.80 14.06 21 34654 3965 32474886
Loss of personal independence in daily activities 16.76 14.06 4 34671 26829 32452022
Aspartate aminotransferase 16.66 14.06 6 34669 126 32478725
Arthritis 16.63 14.06 4 34671 26688 32452163
International normalised ratio increased 16.21 14.06 17 34658 49018 32429833
Blood bilirubin increased 16.19 14.06 83 34592 38701 32440150
Product use issue 16.17 14.06 104 34571 52673 32426178
Antibiotic level below therapeutic 16.17 14.06 5 34670 64 32478787
Deep vein thrombosis 16.05 14.06 27 34648 63686 32415165
Hypersensitivity 15.96 14.06 23 34652 57735 32421116
Hypokalaemia 15.93 14.06 107 34568 54987 32423864
Graft versus host disease in lung 15.86 14.06 9 34666 561 32478290
Periostosis 15.76 14.06 4 34671 23 32478828
Solar dermatitis 15.76 14.06 5 34670 70 32478781
Chondritis 15.75 14.06 6 34669 148 32478703
Malignant neoplasm progression 15.73 14.06 38 34637 78458 32400393
Weight increased 15.61 14.06 42 34633 83621 32395230
Pneumonia bacterial 15.61 14.06 35 34640 10681 32468170
Ephelides 15.56 14.06 5 34670 73 32478778
Delirium 15.52 14.06 90 34585 43956 32434895
Abdominal discomfort 15.51 14.06 20 34655 52604 32426247
Chronic pulmonary histoplasmosis 15.46 14.06 3 34672 3 32478848
Insomnia 15.45 14.06 55 34620 100293 32378558
Apraxia 15.44 14.06 12 34663 1269 32477582
Granulomatous dermatitis 15.41 14.06 7 34668 272 32478579
Escherichia sepsis 15.36 14.06 21 34654 4327 32474524
Lip ulceration 15.35 14.06 10 34665 800 32478051
Fibrinous bronchitis 15.35 14.06 4 34671 26 32478825
Sinusitis fungal 15.18 14.06 8 34667 431 32478420
Candida test positive 15.04 14.06 8 34667 439 32478412
Hepatitis toxic 15.02 14.06 15 34660 2213 32476638
Thrombotic microangiopathy 14.98 14.06 32 34643 9450 32469401
Hypoxia 14.92 14.06 101 34574 52031 32426820
Skin mass 14.86 14.06 19 34656 3670 32475181
Chronic granulomatous disease 14.85 14.06 4 34671 30 32478821
Pneumonia cytomegaloviral 14.73 14.06 17 34658 2955 32475896
Mental disorder due to a general medical condition 14.72 14.06 6 34669 178 32478673
Necrotising ulcerative gingivostomatitis 14.65 14.06 5 34670 89 32478762
Donor leukocyte infusion 14.62 14.06 4 34671 32 32478819
Overdose 14.58 14.06 46 34629 87031 32391820
Injury 14.53 14.06 3 34672 22242 32456609
Blood beta-D-glucan increased 14.49 14.06 8 34667 473 32478378
Musculoskeletal pain 14.45 14.06 8 34667 31889 32446962
Unevaluable event 14.40 14.06 9 34666 33577 32445274
Penicillium infection 14.39 14.06 5 34670 94 32478757
Loss of consciousness 14.34 14.06 43 34632 82664 32396187
Wheezing 14.32 14.06 11 34664 36863 32441988
Dry mouth 14.29 14.06 4 34671 24115 32454736
Haemoptysis 14.17 14.06 72 34603 33453 32445398
Brain herniation 14.14 14.06 19 34656 3852 32474999
Swelling 14.10 14.06 12 34663 38210 32440641

Pharmacologic Action:

SourceCodeDescription
ATC J02AC03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
Triazole and tetrazole derivatives
FDA CS M0002083 Azoles
FDA EPC N0000175487 Azole Antifungal
CHEBI has role CHEBI:50183 cytochrome P450 inhibitor
FDA MoA N0000182140 Cytochrome P450 2C19 Inhibitors
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000185504 Cytochrome P450 2C9 Inhibitors
MeSH PA D058888 14-alpha Demethylase Inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
MeSH PA D065692 Cytochrome P-450 CYP3A Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006727 Hormone Antagonists
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D065088 Steroid Synthesis Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Invasive pulmonary aspergillosis indication 3214003
Candidiasis of the esophagus indication 20639004 DOID:13146
Fusarium infection indication 64250002
Disseminated candidiasis indication 70572005
Candidemia indication 432261003
Fungal Infection due to Scedosporium Apiospermum indication
Fungal Infection due to Fusarium Solani indication
Oropharyngeal Candidiasis off-label use
Hypocalcemia contraindication 5291005
Torsades de pointes contraindication 31722008
Hypokalemia contraindication 43339004
Cardiomyopathy contraindication 85898001 DOID:0050700
Prolonged QT interval contraindication 111975006
Hypomagnesemia contraindication 190855004
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Poor metabolizer due to cytochrome p450 CYP2C19 variant contraindication 424500005
Congenital long QT syndrome contraindication 442917000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.93 acidic
pKa2 2.85 Basic
pKa3 1.42 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
200MG VFEND PF PRISM CV N021266 May 24, 2002 RX TABLET ORAL Jan. 29, 2022 NEW PATIENT POPULATION
50MG VFEND PF PRISM CV N021266 May 24, 2002 RX TABLET ORAL Jan. 29, 2022 NEW PATIENT POPULATION
200MG/VIAL VFEND PF PRISM CV N021267 May 24, 2002 RX INJECTABLE INTRAVENOUS Jan. 29, 2022 NEW PATIENT POPULATION
200MG/5ML VFEND PF PRISM CV N021630 Dec. 19, 2003 RX FOR SUSPENSION ORAL Jan. 29, 2022 NEW PATIENT POPULATION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cytochrome P450 2C9 Enzyme IC50 4.85 CHEMBL
Cytochrome P450 2C19 Enzyme IC50 4.82 CHEMBL
Cholesterol 24-hydroxylase Enzyme Ki 7.96 CHEMBL
Cytochrome P450 3A4 Enzyme IC50 4.89 CHEMBL
Lanosterol 14-alpha demethylase Enzyme INHIBITOR MIC 8.73 WOMBAT-PK CHEMBL
Lanosterol 14-alpha demethylase Enzyme MIC 5.84 WOMBAT-PK
14-alpha sterol demethylase Cyp51A Enzyme Kd 5.44 CHEMBL
14-alpha sterol demethylase Enzyme Kd 6.37 CHEMBL
Cytochrome P450 11A1 Enzyme Kd 5.32 CHEMBL
Sterol 14-alpha-demethylase Enzyme Kd 7.25 CHEMBL
14-alpha sterol demethylase Enzyme Kd 7.25 CHEMBL
14-alpha sterol demethylase Enzyme Kd 7.25 CHEMBL

External reference:

IDSource
4021347 VUID
N0000148767 NUI
D00578 KEGG_DRUG
4021347 VANDF
C0393080 UMLSCUI
CHEBI:10023 CHEBI
VOR PDB_CHEM_ID
CHEMBL638 ChEMBL_ID
DB00582 DRUGBANK_ID
D065819 MESH_DESCRIPTOR_UI
71616 PUBCHEM_CID
7269 INN_ID
JFU09I87TR UNII
121243 RXNORM
16711 MMSL
179944 MMSL
43734 MMSL
d04803 MMSL
009650 NDDF
385469007 SNOMEDCT_US
386116008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VFEND HUMAN PRESCRIPTION DRUG LABEL 1 0049-3160 POWDER, FOR SUSPENSION 40 mg ORAL NDA 34 sections
VFEND HUMAN PRESCRIPTION DRUG LABEL 1 0049-3170 TABLET, FILM COATED 50 mg ORAL NDA 34 sections
VFEND HUMAN PRESCRIPTION DRUG LABEL 1 0049-3180 TABLET, FILM COATED 200 mg ORAL NDA 34 sections
VFEND HUMAN PRESCRIPTION DRUG LABEL 1 0049-3190 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 33 sections
VFEND HUMAN PRESCRIPTION DRUG LABEL 1 0049-3190 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 33 sections
VFEND HUMAN PRESCRIPTION DRUG LABEL 1 0049-3190 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 33 sections
VFEND HUMAN PRESCRIPTION DRUG LABEL 1 0049-4190 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 33 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0378-1626 TABLET, FILM COATED 50 mg ORAL ANDA 31 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0378-1640 TABLET, FILM COATED 200 mg ORAL ANDA 31 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0781-3416 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS ANDA 30 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0781-5667 TABLET, FILM COATED 50 mg ORAL ANDA 30 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0781-5668 TABLET, FILM COATED 200 mg ORAL ANDA 30 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6471 TABLET, FILM COATED 200 mg ORAL ANDA 30 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6596 TABLET 50 mg ORAL ANDA 28 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-7024 TABLET 200 mg ORAL ANDA 27 sections
Voriconazole Human Prescription Drug Label 1 16714-198 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
Voriconazole Human Prescription Drug Label 1 16714-199 TABLET, FILM COATED 200 mg ORAL ANDA 28 sections
Voriconazole Human Prescription Drug Label 1 27241-062 TABLET 50 mg ORAL ANDA 27 sections
Voriconazole Human Prescription Drug Label 1 27241-063 TABLET 200 mg ORAL ANDA 27 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 39822-1077 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 32 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 40032-038 SUSPENSION 40 mg ORAL ANDA 29 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 40032-088 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 40032-089 TABLET, FILM COATED 200 mg ORAL ANDA 28 sections
VORICONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 43386-038 POWDER, FOR SUSPENSION 40 mg ORAL ANDA 29 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 43386-088 TABLET, FILM COATED 50 mg ORAL ANDA 29 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 43386-089 TABLET, FILM COATED 200 mg ORAL ANDA 29 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 43547-377 TABLET, COATED 50 mg ORAL ANDA 18 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 43547-378 TABLET, COATED 200 mg ORAL ANDA 18 sections
VORICONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 47781-466 INJECTION, POWDER, FOR SOLUTION 10 mg INTRAVENOUS ANDA 28 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 51079-164 TABLET, FILM COATED 50 mg ORAL ANDA 31 sections